China-based Beike Biotechnology, a major player in stem cell research and treatment, has signed eight separate mutual cooperation agreements with some of China and the world's most outstanding stem cell research organizations.

As part of the agreements, Beike has also established a "Stem Cell Expert Advisory Committee" and a separate "Data and Safety Monitoring Board (DSMB)" to oversee future Beike-sponsored research.

The eight accords, initially discussed at the recently completed 2008 China Stem Cell Technology Forum held at China Medical City, will deepen Beike's leadership in providing safe, effective, and cutting-edge stem cell treatments to patients from all over the world.

The eight organizations that will share resources, research information, and best practices with Beike Biotech are: AELCELL of Stanford, California; Nanjing Medical University; the China Medical City; Hua Zhong Technical University; the University of Texas Health Science Center at Houston; Jiangsu People's Hospital; the No 2 Hospital of Nanjing Medical University; and the Wu Hu City People's Hospital in Anhui, China.

According to the company release, these mutual cooperation agreements vastly increase Beike's ability to incorporate real-time research information into its network, bolstering Beike's position as the Asian leader and one of the world's foremost biotechnology companies providing stem cell solutions for a range of ailments.

Dr Sean Hu, the Chairman of Beike Biotech, said, "Beike realizes there is definitely strength in numbers when it comes to discovering the latest and best stem cell technologies that will effectively fight a range of terrible diseases. Therefore, we are extremely enthusiastic to be cooperating with eight of the world's leading stem cell research centers, so that together we can more rapidly bring effective treatments to those who need it today."